ClinicalTrials.gg
RecruitingNCT07597707ADHD-HerUpdated May 19, 2026

Investigating Health, Equity, and Resilience in Girls and Women With ADHD Across the Lifespan

An observational study in ADHD, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to female participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by University of Calgary · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,460
Ages
10 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Canada.

Planned enrollment
2nd of 13
1,460 · median 195
Started
2025
the only one that year
Observational
13 of 85
4 open now
Primary completion
2026-12
later than 7 of 15 live
Registered
82nd of 85
by date
Lead sponsor
4 of 85
University of Calgary

Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2025, is one of 13 observational ones, reaches primary completion later than 7 of the 15 other live ones, and was the 82nd registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

12 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 10 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, or all of them as a file.
02

Study summary

The goal of this observational study is to generate a comprehensive, multi-dimensional dataset of health indicators collected from girls and women (aged 10 years and older) with and without ADHD across the lifespan. Participants will be asked to complete a detailed survey about hormonal and developmental life phases, ADHD status and symptoms, childhood experiences, health and well-being, and psychosocial outcomes.

Read the detailed description

The ADHD-Her: Health, Equity and Resilience Study is an observational cross-sectional online study aiming to compile multiple indicators of health and well-being in girls and women with ADHD. We are aiming to enroll at least 1,460 individuals aged 10 years or older who are assigned female at birth or identify as a girl or woman, recruited from communities across Canada. All aspects of the study will be completed remotely, and will be available in both English and French. We will aim to recruit a minimum of 252 participants evenly distributed across five age strata: adolescence (10-17 years); emerging adulthood (18-25 years); early adulthood (26-39 years); middle adulthood (40-54 years); and older adulthood 55+ years). Study participants aged 10-17 years will be enrolled with a parent as a child-parent dyad, where the parent may also fulfill eligibility criteria and complete adult-specific survey measures as an adult participant in addition to participating as a member of the dyad. The sample size was chosen to allow sufficiently powered analyses between and within groupings, providing a controlled means to estimate associations contingent on age, life stage, and diagnostic status. Child participants will be over-recruited with an additional 180 child/parent dyads to account for the multiple processes that occur through this period of development and within group analyses. Some strata may be overrecruited (i.e., 'suspected') to account for inconsistencies in self-report that result in reclassification to control status to ensure all analyses remain adequately powered. Participants will be enrolled on a rolling basis until sample size requirements for each age stratum are met.

Participants will be considered for inclusion in this study if they: 1) were assigned female at birth or gender identity of girl or woman; 2) are fluent in English or French; 3) are aged 10 years or older; 4) currently reside in Canada. Self-reported intellectual disability will be exclusionary. We will enroll participants who have been diagnosed with ADHD by a healthcare practitioner ('ADHD'), who suspect they may have ADHD but have not been formally diagnosed ('Suspected'), or who have neither confirmed nor suspected ADHD ('Control'). The 'suspected' group is intended to capture potential ADHD cases that may have been missed or misdiagnosed, given evidence of high rates of misdiagnosis among girls and women (Attoe \& Climie 2023; Skoglund et al., 2024). Our target enrollment will be 500 'ADHD', 500 'suspected' and 460 'control' participants.

Two protected links to study surveys (one for the parent/guardian to complete and a second for the minor child/adolescent participant to complete) will be emailed to the parent/guardian. Adult participants will acknowledge digital informed consent and assent before accessing the online survey questions. Child respondents will provide assent prior to participation in any study activities.

Recruitment will occur via multiple methods. Advertisements will be posted in communities across Canada (e.g., in medical clinics, ADHD clinics, community centres, etc.) via flyers and posters. In addition, recruitment materials will be posted online through social media posts (e.g., Instagram, Facebook, and LinkedIn), and University websites (e.g., The University of Calgary's 'Participate in Research' website). Potential participants will also be free to share recruitment information through their personal social media/email platforms or forward recruitment information to others, and study collaborators will disseminate recruitment information through their available channels and through community partner organizations. Lastly, eligible participants who have previously enrolled in our research studies and have consented to be contacted for future studies will be invited to participate.

Interested participants will contact the study team via an email address provided on the recruitment materials in order to receive a link to an online screening survey, described below. Alternatively, interested participants can access the screener survey directly through posted links or QR codes on recruitment materials. This screening survey aims to ensure they meet the inclusion criteria and to screen out any automated computer-generated responders. Eligible respondents will then receive an email link to the online study survey, described below, along with a written description of the study's design, purpose, risks and benefits, and ongoing rights to rescind consent. They will also provide consent by electronically signing an informed consent form prior to participation in any study measures.

All surveys will be completed via personal computer, tablet, or mobile phone using secured Qualtrics data collection software hosted through the University of Calgary. All surveys will be accessible in either English or French. In the event no personal device is available, a research assistant will be made available to assist participants in completing their survey responses via telephone or through the secured teleconferencing platform Microsoft Teams, hosted through the University of Calgary Information Technologies department to ensure that the software used is encrypted and complies with local legal requirements to protect the personal health information of all participants. All participants will be given the opportunity to provide feedback and elaborate on their responses via an open-ended comment option that will be available as the final component of their survey. Surveys will take approximately 30 to 60 minutes to complete. Adult and parent/guardian participant surveys will take approximately 30-60 minutes to complete and child/adolescent surveys will take approximately 30-45 minutes to complete. Breaks in answering survey items will be provided as needed, in which responses will be saved, and survey progress can be continued at any time the participant returns to the survey.

A screening survey will allow participants to indicate if they meet any of the inclusion and/or exclusion criteria before participating in the full study. It will provide a brief overview of the purpose of the study, and a reCAPTCHA response item for participants to click to indicate they are not a robot responder. All participants will be asked to indicate their sex, gender, whether they reside outside of Canada, their residential province, whether they speak English or French, and whether they have been diagnosed with intellectual disability. Participants who meet these criteria will then be asked to generate a unique and anonymized participant ID using the first three letters of their mothers' maiden name, and the two-digit number from the day of the month of their birthdate. For example, someone born September 15 whose mother's maiden name was "Smith," would generate a participant ID of "SMI15." These data will ensure participation in the study survey is limited to only those who met inclusion criteria, while also removing identifying information from any subsequently collected data. To link familial data, participants will be asked to indicate if any family members are also participating in the study, and to indicate how they are related. Participants will additionally enter their preferred email address, and should they meet study criteria, will be emailed a copy of the written informed consent document for adult participants, and written informed assent document for minor participants, and a unique link to the full study survey to consent and participate. Completion of this survey should take 1-5 minutes.

Multiple safeguards will be implemented within the screening survey to preserve the integrity of the data and prevent computer-generated responders. First, participants will respond to an open-text question asking, "Briefly, tell us where you heard about this study." Additionally, respondents will be shown hidden text (white font on a white background) instructing them to include the word "banana" in their response. Since only automated bots will detect and follow this instruction, any responses containing "banana" can be filtered out. Participants will also be asked to provide free-text responses following certain parameters (e.g., using specific words) which will further allow us to identify authentic respondents, as well as geolocation data to validate consistency in reported residential province. Embedded data collection measures, such as tracking the number of pastes, keys typed, backspaces used, and speed of completion will be used to further identify authentic and inauthentic responses. Comparisons between responses in the pre-screening survey and the full study survey provide a further validity check to ensure data quality. No further information on familial relations will be asked at the pre-screening stage, but this will allow research assistants to follow up via email, to ensure familial participant responses are linked appropriately in the full study survey.

The full study survey will include questions about sociodemographic details, hormonal and developmental life phases, ADHD status and symptoms, childhood experiences, health and well-being, and psychosocial outcomes. Participants who are parents will also report on aspects of their parent/guardian-child relationship and child behaviour. Where possible, short-form or adapted/shortened measures will be used to reduce participant burden. Additionally, branching logic will be used to display questions, in which only relevant questions will be shown to participants based on their previous answers, and where applicable, an "other" option with a text box for responding will be provided. This online survey should take approximately 30-60 minutes for those aged 18 years or older, and 30-45 minutes for each child/adolescent and their guardians.

The following measures will be administered:

Sociodemographic Characteristics - Demographic Questionnaire (Study-developed): Assesses age, date of birth, sex assigned at birth, gender, sexual orientation, ethnicity, language fluency, geographic location, education, income, residence status, marital status, occupational status, and subjective health. Respondents: adult participants, parent/guardian, child/adolescent participants.

ADHD Diagnostic Status - Diagnostic History Questionnaire (Study-developed): Assesses no ADHD diagnosis, suspected but not diagnosed ADHD, or confirmed clinician-diagnosed ADHD. Collects additional information on ADHD presentation, age of symptom onset, age of diagnosis or suspicion, diagnosing clinician, medication use, and consistency of medication use. Respondents: adult participants, parent/guardian, child/adolescent participants.

ADHD-Related Service Access and Barriers - Health Access Questionnaire (Study-developed): Assesses where participants access ADHD-related information and resources, confidence or satisfaction in physician ADHD knowledge, and perceived obstacles to accessing ADHD information, resources, or diagnostic identification. Respondents: adult participants, parent/guardian, child/youth participants.

Developmental/Hormonal Life Stage - Developmental Life Stage Questionnaire (Study-developed): Assesses current developmental or hormonal stage, including pre-puberty, active puberty, completed puberty, pregnancy, postpartum, perimenopause, or menopause. Respondents: adult participants, parent/guardian, child/youth participants.

Mental Health History and Medication Use - Mental Health Comorbidity and Medication History Questionnaire (Study-developed): Assesses self-reported mental health history, comorbidities, and psychiatric medication use, including depression, anxiety, OCD, bipolar disorder, personality disorders, conduct disorder, oppositional defiant disorder, learning disorders, and other mental health challenges. Respondents: adult participants, parent/guardian, child/adolescent participants.

Menstrual, Reproductive, and Contraceptive Health History - Menstrual Health Questionnaire (Study-developed): Assesses menstrual health history, contraceptive use, hormonal replacement therapy, and women's reproductive health conditions. Respondents: adult participants, child/adolescent participants who have reached menarche.

Adult ADHD Symptoms - Adult ADHD Self-Report Scale, v.1.1 (ASRS-v1.1) (Kessler et al., 2005): Assesses current ADHD symptoms in adults, including inattention and hyperactivity/impulsivity. Used as a validated adult ADHD screener and symptom measure. Respondents: adult participants (age 18+).

Child/Adolescent ADHD Symptoms - Conners-4th Edition Short Self-Report Form ADHD Index (Conners, 2023): Assesses youth self-reported ADHD symptoms. Respondents: child/adolescent participants (age 10-17).

Child/Adolescent ADHD Symptoms (Observer) - Conners-4th Edition Short Parent Report ADHD Index (Conners, 2023): Assesses parent-reported ADHD symptoms in child/adolescent participants. Respondents: parent/guardian.

Emotion Regulation - Difficulties in Emotion Regulation Scale (DERS) (Gratz \& Roemer, 2004): Assesses difficulties with emotion regulation, including emotional awareness, clarity, impulse control, goal-directed behaviour, nonacceptance of emotional responses, and access to emotion regulation strategies. Respondents: adult participants (age 18+).

Positive Childhood Experiences - Positive Childhood Experiences Scale (PCEs) (Bethell et al., 2019): Assesses retrospective positive childhood experiences and early relational or contextual strengths. Respondents: adult participants (age 18+).

Adverse Childhood Experiences - BRFSS ACE Module (Centers for Disease Control and Prevention, n.d.): Assesses retrospective exposure to adverse childhood experiences. Respondents: adult participants (age 18+).

Self-Esteem - Rosenberg Self-Esteem Scale (RSES (Rosenberg, 1965): Assesses global self-esteem. Respondents: adult participants; select child/youth participants. Ages 18+; 12-17.

Self-Compassion - Self-Compassion Scale - Short Form (SCS-SF (Raes et al., 2011): Measures self-reported self-kindness, mindfulness, common humanity, and reduced self-judgment. Respondents: adult participants (age 18+).

Loneliness - Revised UCLA Loneliness Scale (Russell, 1996): Assesses perceived loneliness and social isolation. Respondents: adult participants (age 18+).

Mattering/Anti-Mattering - General Mattering Scale (GMS) (Flett, Nepon, \& Hewitt, 2022): Assesses perceived importance, significance, and feeling valued by others. Respondents: adult participants, child/adolescent participants. Ages 10+.

Resilience - Brief Resilience Scale (Smith et al., 2008): Measures perceived ability to recover or "bounce back" from stress. Respondents: adult participants (age 18+).

Shame/Guilt - Harder Personal Feelings Questionnaire-2 Brief (Harder \& Zalma, 1990): Assesses proneness to shame and guilt. Respondents: adult participants (age 18+).

Masking - Adult ADHD Masking Measure (Behavioral Health Consulting Solutions, 2024): Assesses compensatory strategies and masking or camouflaging of ADHD-related difficulties. Respondents: adult participants (age 18+).

Romantic Relationship Quality - Relationship Assessment Scale (RAS) (Hendrick, 1988): Measures satisfaction and perceived quality in romantic relationships. Respondents: adult participants (age 18+).

Perceived Social Support - Interpersonal Support Evaluation List (ISEL) (Cohen, 1985): Assesses perceived availability of social support. Respondents: adult participants (age 18+).

Health Status - Subjective Rating of Health (Statistics Canada, single-item): Captures global self-rated health. Respondents: adult participants, parent/guardian, child/adolescent participants. All age groups.

Quality of Life/Life Satisfaction - Satisfaction with Life Scale (Diener, Emmons, Larsen, \& Griffin, 1985): Assesses global cognitive judgments of life satisfaction. Respondents: adult participants (age 18+).

Life Stress - Holmes-Rahe Life Stress Inventory (Holmes \& Rahe, 1967): Assesses cumulative exposure to major life events and associated stress burden. Respondents: adult participants. Respondents: adult participants (age 18+).

Attachment - Attachment Style Questionnaire (ASQ) (Feeney, Noller, \& Hanrahan, 1994): Assesses attachment style and interpersonal security or insecurity. Respondents: adult participants; select child/adolescent participants.

Physical Activity - International Physical Activity Questionnaire (I-PAQ) (Craig et al., 2003): Assesses physical activity and sedentary behaviour. Respondents: adult participants; select child/adolescent participants. Ages 18+; 15-17.

Sleep Quality - Brief Pittsburgh Sleep Quality Index (Sancho-Domingo et al., 2020): Brief assessment of sleep quality and sleep disturbance.

Cognitive Functioning - Cognitive Failures Questionnaire (CFQ) (Broadbent, Cooper, FitzGerald, \& Parkes, 1982): Assesses everyday cognitive lapses in attention, memory, perception, and action. Respondents: adult participants; select child/adolescent participants. Ages 18+; 16-17.

Mental Health (Depression, Anxiety, and Stress) - Depression Anxiety Stress Scales - 18-item Version (DASS-18) (Keislaman, 2024; Lovibond \& Lovibond, 1995): Assesses symptoms of depression, anxiety, and stress. Respondents: adult participants (age 18+).

Parent Self-Stigma - Parent's Self-Stigma Scale (PSSS) (Eaton, Ohan, Stritzke, \& Corrigan, 2019): Assesses parental self-stigma, including self-blame, shame, and negative beliefs related to a child's difficulties. Respondents: adult participants (age 18+).

Parent/Child Relationship - BASC-3 Parenting Relationship Questionnaire (BASC-3-PRQ) (Reynolds, 2015): Assesses parent-child relationship quality, including involvement, communication, discipline, attachment, and relational functioning. Respondents: adult participants, parent/guardians. Ages 18+.

Child/Adolescent Behavioural and Emotional Functioning - Behavior Assessment System for Children - Third Edition, Parent Rating Scales (BASC-3) (Reynolds \& Kamphaus, 2015): Assesses behavioural and emotional functioning in children and adolescents. Respondents: parent/guardians, adult participants. Ages 18+.

03

Conditions studied

  • ADHD

Keywords

  • ADHD
  • women
  • woman
  • girl
  • girls
  • female
  • females
  • hormone
  • hormones
  • hormonal
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Recruitment will occur via multiple methods. Advertisements will be posted in communities across Canada (e.g., in medical clinics, ADHD clinics, community centres, etc.) via flyers and posters. In addition, recruitment materials will be posted online through social media posts (e.g., Instagram, Facebook, and LinkedIn), and University websites (e.g., The University of Calgary's 'Participate in Research' website). Potential participants will also be free to share recruitment information through their personal social media/email platforms or forward recruitment information to others, and study collaborators will disseminate recruitment information through their available channels and through community partner organizations. Lastly, eligible participants who have previously enrolled in our research studies and have consented to be contacted for future studies will be invited to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Assigned female at birth or identify as girl or women
  • Fluency in English or French
  • Aged 10 years or older
  • Currently reside in Canada
  • Access to technology to complete study measures

Exclusion criteria

Exclusion Criteria:

  • Self-reported intellectual disability
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,460 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diagnosed ADHD

    Participants who self-report that they have been diagnosed with ADHD by a healthcare practitioner.

    Other: No Intervention: Observational Cohort

  • Suspected ADHD

    Participants who self-report that they suspect they have ADHD but have not received a formal diagnosis.

    Other: No Intervention: Observational Cohort

  • Controls

    Participants who neither have a self-reported diagnosis of ADHD, nor suspect they have ADHD.

    Other: No Intervention: Observational Cohort

Interventions

  • OtherNo Intervention: Observational Cohort

    This is an observational study with no intervention. Participants will only complete self-report questionnaires.

06

What researchers measure

Primary outcomes

  1. Self-reported mental health

    Self-reported mental health history (assessed using a study-developed questionnaire querying current depression, anxiety, OCD, bipolar disorder, personality disorders, conduct disorder, oppositional defiant disorder, learning disorders, and other mental health challenges, as well as medication use for these conditions). This is a check list of disorders in which participants can self-identify diagnoses. There is no minimum/maximum.

    Time frame: baseline (upon entry into study)

  2. Depression, anxiety, and stress

    Depression, anxiety, and stress measured using the 18-item Depression Anxiety Stress Scales. Participants are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week. Scores for Depression, Anxiety and Stress are calculated by summing the scores for the relevant items. Higher scores are indicative of greater distress.

    Time frame: baseline (upon entry into study)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) may be shared with other researchers after data collection is complete and after publication of study results. Data sharing will only take place with permission of the principal investigator and in accordance with participant consent, applicable privacy regulations, and institutional data management policies. Data will be shared in coded form for scientific research purposes only and may require a data sharing agreement. Requests for access to the data can be submitted to the principal investigator.

Supporting information: Study protocol, Analytic code

Time frame: Individual participant data and supporting materials will become available after data collection is complete. Data will be available upon reasonable request for scientific research purposes, subject to approval by the principal investigator and in accordance with participant consent and applicable privacy regulations. Data will remain available indefinitely after completion of the study.

Access criteria: Researchers may request access to de-identified individual participant data (IPD) and related materials for scientific purposes. Accessible materials include the de-identified dataset, along with the study protocol and analytic code. Access requests should be directed to the principal investigator, who will review and approve them in line with participant consent, applicable privacy regulations, and institutional data governance policies. Approved data sharing may be facilitated through a formal data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 19, 2026
StartActual
Aug 25, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07597707
Responsible party
Emma Climie (Associate Professor, University of Calgary) — Principal investigator
First posted
May 19, 2026
Start date
Aug 25, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 19, 2026

Study contacts

Emma A Climie, PhD
Contact
eaclimie@ucalgary.ca
403-220-7770
Brandy L Callahan, PhD
Contact
brandy.callahan@ucalgary.ca
4032207291
Emma A Climie, PhD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion